NIKA (Nika Pharmaceuticals) Beginning Cash Position: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NIKA Nika Pharmaceuticals Inc NIKA
12 GF Score
Price $0.41
! 3 Warning Signs
View Full Analysis

What is Nika Pharmaceuticals Beginning Cash Position?

Nika Pharmaceuticals NIKA 12 Beginning Cash Position is $0.00 Mil as of Jun. 2026. GuruFocus rates NIKA with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

Nika Pharmaceuticals's Beginning Cash Position for the quarter that ended in Jun. 2026 was $0.00 Mil.

Nika Pharmaceuticals's quarterly Beginning Cash Position declined from Dec. 2025 ($0.01 Mil) to Mar. 2026 ($0.00 Mil) but then increased from Mar. 2026 ($0.00 Mil) to Jun. 2026 ($0.00 Mil).

Nika Pharmaceuticals's annual Beginning Cash Position increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.02 Mil) but then declined from Dec. 2024 ($0.02 Mil) to Dec. 2025 ($0.00 Mil).

Nika Pharmaceuticals Beginning Cash Position Related Terms

Nika Pharmaceuticals Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Nika Pharmaceuticals's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nika Pharmaceuticals Beginning Cash Position Chart

Nika Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 0.00 0.00 0.00 0.02 0.00

Nika Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.01 0.00 0.00
NIKA
12GF Score
Nika Pharmaceuticals Inc NIKA
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nika Pharmaceuticals Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $0.00 Mil mean?
Nika Pharmaceuticals (NIKA) has a Beginning Cash Position of $0.00 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Nika Pharmaceuticals and its competitors.
Is Nika Pharmaceuticals' Beginning Cash Position too high?
Nika Pharmaceuticals' current Beginning Cash Position is $0.00 Mil. Overall, Nika Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Nika Pharmaceuticals' Beginning Cash Position compare to ESPR and AMPH?
Nika Pharmaceuticals' Beginning Cash Position of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Nika Pharmaceuticals and its competitors. Nika Pharmaceuticals's current Beginning Cash Position is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nika Pharmaceuticals stock overvalued right now?
Nika Pharmaceuticals (NIKA) has a current Beginning Cash Position of $0.00 Mil. The current Beginning Cash Position is $0.00 Mil. Nika Pharmaceuticals' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Nika Pharmaceuticals (NIKA), the current Beginning Cash Position is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nika Pharmaceuticals Business Description

Address 2269 Merrimack Valley Avenue, Henderson, NV, USA, 89044
Nika Pharmaceuticals Inc is a company involved in development and distribution of a variety of pharmaceutical products, including dietary supplements and antiviral drugs. It has acquired the exclusive rights for production and distribution of the dietary supplements Physiolong and Carotilen, as well as the drug TNG, which has been clinically tested on AIDS patients.
12GF Score

Get the complete analysis for NIKA

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.41
Price